Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What?
State by state, hemp industry opening like a flower.
FLOODGATES
House committee OK's bill to allow interstate hemp shipments
By REBECCA BOONE Associated Press | Posted: Sat 2:01 PM, Apr 06, 2019
BOISE, Idaho (AP) - Legislation that would allow people to transport hemp through Idaho if they first get a permit from the Idaho Department of Agriculture director has won the approval of a House committee.
The legislation sponsored by Republican Reps. Judy Boyle of Midvale and Caroline Nilsson Troy of Genesee, would treat the transportation of hemp similarly to how the state treats the transportation of livestock, with out-of-state carriers required to get a permit and then comply with Idaho State Police checkpoints at specific state entry points.
Phil Haunschild with the Idaho Freedom Foundation testified against the bill, saying its intent was noble but that it would cause problems for companies and truckers who ship hemp from state to state under their own state permits and don't realize Idaho has its own special rules.
Source: https://www.kmvt.com/content/news/House-committee-OKs-bill-to-allow-interstate-hemp-shipments-508185431.html
States move to legalize CBD to end confusion over US rules
By: ALLISON BRUHL
Posted: Apr 06, 2019 02:33 PM CDT
Updated: Apr 06, 2019 02:33 PM CDT
SAN FRANCISCO (AP) — (4/6/19) CBD oil-infused gummy bears, lattes and other food, drinks and dietary supplements are selling quickly even though the U.S. government says they're illegal and local authorities have forced some retailers to pull products. The confusion has the nation's two largest states and others moving to legalize the cannabis compound that many see as beneficial to their health.
Lawmakers in Texas and California are often in opposition, but they're both pushing bipartisan legislation to sidestep federal law and allow sales of the compound found in hemp and marijuana. Republicans and Democrats in Congress also are urging the U.S. Food and Drug Administration to change its stance.
The FDA announced Tuesday that it will hold a public hearing in May to gather more information.
Resolving the confusion can't come quick enough for Jonathan Eppers, who makes Vybes, a popular CBD oil-infused beverage. California health inspectors raided his Los Angeles warehouse in January and impounded $100,000 worth of the drink.
Eppers said about 50 California retailers have since dropped his product and he's moved production to Texas. He estimates lost sales, legal costs and relocation expenses have cost him at least $500,000.
"What is going on is unbelievable and asinine," Eppers said. "They put us in this state of limbo that's costing us."
Eppers and CBD fans are mystified by the legal insecurity. After all, they say, retailers in California and nine other states that have broadly legalized marijuana sell edibles and other products that get people high, though pot is illegal under federal law. U.S. officials generally have taken a hands-off approach in states where pot is legal.
The FDA has oversight of CBD because it is the active ingredient in an approved prescription drug to treat two rare seizure disorders. The agency says CBD can't be added to food or sold as a dietary supplement because officials haven't determined if it's safe or effective for other conditions.
FDA Commissioner Scott Gottlieb told Congress last week that enforcement is being limited to sellers who make false health claims. He says the agency recently sent warning letters to three companies touting CBD as a treatment for cancer, Alzheimer's disease, fibromyalgia and drug addiction.
"But there are products on the market right now that, given our enforcement priorities and our limited resources, we haven't taken action against," he said.
Short for cannabidiol, CBD is a non-intoxicating molecule found in hemp and marijuana. Both are cannabis plants, but only marijuana has enough of the compound THC to get users high.
CBD oil is extracted when the plant is processed. While hemp derivatives are essentially THC-free, CBD oil from marijuana may have very little or enough to produce a high.
Sellers and users say CBD helps with pain, anxiety and inflammation, though limited scientific research supports those claims. It's turning up in products ranging from lotions, cosmetics and soap to diet pills, juices, cocktails, candy and drinks.
State and local officials are taking nearly all the enforcement actions against CBD. Health officials in California, which has the nation's largest legal marijuana marketplace, warned retailers last summer that anything edible containing CBD is illegal until lawmakers or regulators say otherwise.
The warning was largely ignored until earlier this year, when state and local health officials began forcing some small businesses to pull products after receiving complaints.
San Francisco health officials recently barred two small operators from selling CBD-infused food and drink, while authorities in rural Grass Valley, 140 miles (308 kilometers) away, did the same to a small, cooperatively owned grocery store.
"It caught us way off guard," said Gus Dabais, owner of Sidewalk Wellness, one of the stores targeted.
The San Francisco Health Department sent warning letters to 1,900 businesses last year, spokeswoman Veronica Vien said. She said inspectors are not looking for CBD but responding to complaints.
She said that's how they ended up "red tagging" products at Dabais' business and Steap Tea Bar, a popular Chinatown stop that sold CBD-infused bubble tea.
Similar scenarios are playing out in Ohio, where authorities in January ordered a Cincinnati grocery store to remove CBD from two outlets. The following month, New York City health inspectors removed CBD products from a number of restaurants. Police in March raided two Fort Worth, Texas, retailers and seized CBD products after the local district attorney declared the compound illegal.
In Texas, one of a handful of states that outlaws all forms of marijuana, lawmakers are pushing a measure that would legalize hemp oil-infused edibles. It sailed through its first committee in the House this week.
In California, a similar CBD measure has moved on to the full Assembly.
"A number of people have been using it for years, and you can find it on retail shelves all over the place, but now people are surprised to find it's against the law," said Assemblywoman Cecilia Aguiar-Curry, a Napa-area Democrat who introduced the measure. "What this bill will do is clear up the confusion."
She said the legislation would stop state and local enforcement of the FDA's ban and hopes it becomes law by August.
"This would lift a legal cloud from a legitimate California business," said Jim Gross of the U.S. Hemp Roundtable, an industry association.
A growing number of federal lawmakers, including Senate Majority Leader Mitch McConnell and Democratic Sen. Ron Wyden of Oregon, are urging the FDA to approve CBD. They backed a measure taking hemp off the U.S. government's list of banned substances.
"Hemp is a versatile crop with many uses and applications," McConnell and Wyden wrote to the FDA in February. "We are hopeful that by working with you on the implementation of our legislation, we can help ensure that hemp can be a new cash crop for farmers across the country."
Source: https://www.myarklamiss.com/news/states-move-to-legalize-cbd-to-end-confusion-over-us-rules/1904861871
How many acres of hemp required for decorticator to be economical?
Hundreds?
Thousands?
Tens of thousands?
Hemp Inc farmer network scales up fast.
Who?
FIRST THURSDAY TOURS!
https://www.facebook.com/KingOfPot/videos/pcb.10217222738896995/10217222735736916/?type=3&theater
FREE FOR SHAREHOLDERS ONLY.
Hey, guess that means even shorts could attend for free?
Some have already attended Hemp U, wanted to learn from the best.
Industrial Hemp Is The Answer To Petrochemical Dependency
https://www.forbes.com/sites/ellistalton/2019/04/04/industrial-hemp-is-the-answer-to-petrochemical-dependency/#68295e672d8c
Hemp Clothing Is Happening, and No, It Won’t Get You High
https://www.wsj.com/articles/hemp-clothing-is-happening-and-no-it-wont-get-you-high-11554404607
MIRROR MIRROR ON THE WALL
Who's the sleaziest of them all?
McCloy...
Kuznetsov...
Yudell...
Which one of these HEMP ratbaits will survive?
Find out next time...
WHO'S GONNA PROCESS ALL THE HEMP?
HEMP INC -- CBS NEWS
https://www.cbs17.com/news/local-news/nc-hemp-processing-facility-is-largest-in-western-hemisphere/1103849580
HEMP INC -- NBC NEWS
https://kobi5.com/news/hemp-the-burgeoning-industry-of-southern-oregon-92209/
HEMP INC -- ABC NEWS
https://www.abc15.com/news/state/farmers-could-plant-hemp-in-arizona-fields-this-summer-if-bill-passes
HEMP INC -- WASHINGTON TIMES
https://www.washingtontimes.com/news/2018/dec/11/senate-passes-867-billion-farm-bill/
HEMP INC -- FORBES
https://www.forbes.com/sites/andrebourque/2019/03/25/how-hemp-is-giving-renewed-life-to-americas-tobacco-farmers/#434da3f84726
https://www.forbes.com/sites/andrebourque/2018/12/17/how-hemp-and-the-farm-bill-may-change-life-as-you-know-it/#4f98a6a8694c
HEMP INC -- CRAINS
http://www.crains.com/article/news/north-carolina-growers-are-betting-hemp
HEMP INC -- FOX BUSINESS
https://www.foxbusiness.com/small-business/hemp-ceo-thanks-to-farm-bill-the-hemp-revolution-will-now-be-made-in-america
HEMP INC -- THE BUSINESS JOURNAL
https://thebusinessjournal.com/farm-bill-talks-invigorate-hope-for-hemp-in-the-valley/
HEMP INC -- COLORADO SPRINGS INDEPENDENT
https://www.csindy.com/coloradosprings/hemp-incs-new-product-makes-oil-drilling-a-bit-more-eco-friendly/Content?oid=14668202
HEMP INC -- SPECTRUM NEWS
https://spectrumlocalnews.com/nc/triangle-sandhills/news/2018/09/02/carolina-hemp-festival-educates-public-about-many-uses-of-hemp
HEMP INC -- ROCKY MOUNT TELEGRAM
http://www.rockymounttelegram.com/News/2018/07/28/Area-hemp-plant-inks-new-distribution-deal.html
HEMP INC -- THE WILSON TIMES
http://www.wilsontimes.com/stories/raising-hemp-a-lucrative-but-risky-business-endeavor,152622
http://wilsontimes.com/stories/carolinas-next-cash-crop,155136
HEMP INC -- CARRIBEAN BUSINESS
https://caribbeanbusiness.com/industrial-hemp-sustainable-economic-development-for-p-r/
HEMP INC -- KDKA RADIO
https://kdkaradio.radio.com/media/audio-channel/hemp-farming-act-2018
HEMP INC -- THE OREGONIAN
https://www.oregonlive.com/politics/2018/12/oregon-hemp-industry-poised-for-big-growth-after-feds-sign-off.html
HEMP INC -- MASS LIVE
https://www.masslive.com/news/2018/12/the-federal-government-is-about-to-legalize-hemp-what-does-it-mean-for-massachusetts.html
WATCH---HEMP INC GROWING, PROCESSING, & SHIPPING HEMP
https://www.facebook.com/KingOfPot/videos/pcb.10217128448259788/10217128456099984/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10217128448259788/10217128479380566/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216944818829167/10216944817629137/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216944818829167/10216944827509384/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216944818829167/10216944846109849/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216937472445512/10216937468805421/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216937472445512/10216937479325684/?type=3&theater
https://www.facebook.com/KingOfPot/videos/10216341909436809/
https://www.facebook.com/KingOfPot/videos/10216335888526290/
https://www.facebook.com/KingOfPot/videos/10216330020819601/
https://www.facebook.com/KingOfPot/videos/pcb.10216154785518828/10216154816239596/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216102687736416/10216102686136376/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216196627844860/10216196635405049/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10216040924112364/10216040917992211/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10215806930262664/10215806932622723/?type=3&theater
https://www.facebook.com/KingOfPot/videos/pcb.10215568627025232/10215568648105759/?type=3&theater
TOURING POTENTIAL MASSIVE HEMP-HUB IN PUERTO RICO
https://www.facebook.com/KingOfPot/videos/10216757569348047/
https://www.facebook.com/KingOfPot/videos/10216757588108516/
https://www.facebook.com/KingOfPot/videos/10216476607324172/
https://www.facebook.com/KingOfPot/videos/10216469874395853/
TOURING POTENTIAL MASSIVE HEMP PROCESSING FACILITY IN CENTRAL FLORIDA
https://www.facebook.com/KingOfPot/videos/10216659709101602/
'HEMP UNIVERSITY', SATURDAY, MARCH 23RD, MEDFORD, OREGON
https://www.thehempuniversity.com/
https://www.facebook.com/KingOfPot/videos/pcb.10217141800193578/10217141853834919/?type=3&theater
NORTH CAROLINA INDUSTRIAL HEMP REGISTERED PROCESSORS (APRIL 2019)
https://www.ncagr.gov/hemp/documents/IHProcessorList4_1_19.pdf
NORTH CAROLINA INDUSTRIAL HEMP REGISTERED PROCESSORS (APRIL 2019)
https://www.ncagr.gov/hemp/documents/IHProcessorList4_1_19.pdf
Now several hundred registered processors and counting in program's 3rd year.
Hemp Inc's 'IHM' one of original 10 state processors, beginning day-1.
Industrial hemp was legalized at the national level three months ago, with a YUGE spring sowing days away...
Hemp "years ahead of the competition" as most everybody can see!
U.S. Senators Push Federal Bank Regulators To Clarify Rules For Hemp Businesses
Published on April 2, 2019 By Kyle Jaeger
A bipartisan duo of top U.S. senators sent a series of letters to federal financial regulators on Tuesday, imploring them to provide guidance to banks on the laws governing servicing hemp businesses.
Senate Majority Leader Mitch McConnell (R-KY) and Sen. Ron Wyden (D-OR), chief proponents of a hemp legalization provision that was included in the 2018 Farm Bill, sent the requests to the Federal Deposit Insurance Corporation (FDIC), the Office of the Comptroller of the Currency (OCC), the Federal Reserve System and the Farm Credit Administration (FCA).
“As authors of the Hemp Farming Act, McConnell and Wyden are committed to listening to the concerns of hemp farmers and producers and to urging federal agencies to properly implement the law,” the senators’ offices said in a press release.
The letters all share a section that discusses how the senators’ home states of Kentucky and Oregon have “been on the forefront of hemp production ever since the authorization of industrial hemp pilot programs” in 2014 and how hemp farmers and cultivators are “excited to explore the full economic opportunities for hemp after the passage of the 2018 Farm Bill.”
A bipartisan duo of top U.S. senators sent a series of letters to federal financial regulators on Tuesday, imploring them to provide guidance to banks on the laws governing servicing hemp businesses.
Senate Majority Leader Mitch McConnell (R-KY) and Sen. Ron Wyden (D-OR), chief proponents of a hemp legalization provision that was included in the 2018 Farm Bill, sent the requests to the Federal Deposit Insurance Corporation (FDIC), the Office of the Comptroller of the Currency (OCC), the Federal Reserve System and the Farm Credit Administration (FCA).
“As authors of the Hemp Farming Act, McConnell and Wyden are committed to listening to the concerns of hemp farmers and producers and to urging federal agencies to properly implement the law,” the senators’ offices said in a press release.
The letters all share a section that discusses how the senators’ home states of Kentucky and Oregon have “been on the forefront of hemp production ever since the authorization of industrial hemp pilot programs” in 2014 and how hemp farmers and cultivators are “excited to explore the full economic opportunities for hemp after the passage of the 2018 Farm Bill.”
FDA Announces Details On CBD Public Hearing
Published on April 2, 2019 By Kyle Jaeger
The Food and Drug Administration (FDA) will hold a public hearing on regulating hemp-derived CBD on May 31, the agency announced in a notice scheduled to be published in the Federal Register on Wednesday.
The much-anticipated hearing will feature testimony from stakeholders and is aimed at informing FDA’s regulatory approach to CBD products. Outgoing FDA Commissioner Scott Gottlieb, who initially said the meeting would take place sometime in April, has repeatedly stressed that while the 2018 Farm Bill federally legalized hemp and hemp-derived products, CBD products remain under the agency’s purview.
Because CBD is an FDA-approved drug in the form of prescription medication Epidiolex and hasn’t been previously introduced into the food supply, regulating CBD products is especially complicated, Gottlieb has said. However, there are alternative pathways the agency can pursue, and the public hearing is one of the first steps in that rulemaking process.
“The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products,” the agency wrote. “FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products.”
FDA listed a number of “unanswered questions” that it hopes will be addressed at the hearing.
Are there any “particular safety concerns that FDA should consider” as far as regulating CBD products is concerned? Should any specific populations like pregnant women be taken into consideration when developing regulations for CBD? What’s the “maximal acceptable daily intake from all products?”
The notice also discusses why CBD’s status as an approved drug for the treatment of certain forms of epilepsy complicates its regulatory responsibility. If the ingredient is allowed in the food supply or as dietary supplements, there’s a risk that companies will have less of an incentive to conduct additional clinical trials investigating its therapeutic potential, FDA said.
Beyond the public safety issues, FDA listed more questions about the manufacturing and marketing of CBD products. It’s soliciting input on the safest practices for manufacturing CBD and how to properly notify consumers about health risks through labeling, among other topics.
“The public hearing will give stakeholders an opportunity to provide the FDA with additional input relevant to the agency’s regulatory strategy related to existing products, as well as the lawful pathways by which appropriate products containing cannabis or cannabis-derived compounds can be marketed, and how we can make these legal pathways more predictable and efficient,” Gottlieb said in a new statement accompanying the Federal Register notice. “We hope to gain additional information and data for the FDA to consider with respect to products containing cannabis and cannabis-derived compounds, including CBD.”
He also provided new details about an FDA working group tasked with exploring “potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed; including a consideration of what statutory or regulatory changes might be needed and what the impact of such marketing would be on the public health.”
The agency also updated a cannabis products questions-and-answers page on its website with new information.
FDA said it’s aware that there are companies that are already marketing CBD products, including cases where the companies have been formally warned about making unauthorized medical claims about the products. Gottlieb hinted at the agency’s enforcement priorities at a congressional hearing last week.
Hemp cultivators and processors are eager to receive federal guidance on CBD, but the commissioner has tried to temper expectations about the timeline for that guidance. Without congressional action that specifically targets CBD, it may be years before the regulations are enacted, he said.
In the meantime, people interested in shaping the FDA’s CBD regulatory process can submit public comments through July 2. The agency says it will soon make information on how to register for the public hearing available online.
The U.S. Department of Agriculture held a lengthy public hearing last month to receive input from stakeholders about its efforts to implement the Farm Bill’s hemp legalization provisions more generally.
Source: https://www.marijuanamoment.net/fda-announces-details-on-cbd-public-hearing/
FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks
PUBLISHED TUE, APR 2 2019 • 8:53 AM EDT | UPDATED TUE, APR 2 2019 • 6:52 PM EDT
The Food and Drug Administration has set its first public hearing on legalizing CBD in food and drinks, to figure out how to regulate the newly legalized cannabis product. The hearing will take place on May 31.
The agency wants data on CBD’s safety in food products and feedback on how it might regulate manufacturing, marketing and labeling, according to a notice posted Tuesday in the Federal Register.
Outgoing FDA Commissioner Scott Gottlieb named Principal Deputy Commissioner Amy Abernethy and Principal Associate Commissioner for Policy Lowell Schiller to co-chair a high-level working group tasked with evaluating the issue.
“It’s critical that we address these unanswered questions about CBD and other cannabis and cannabis-derived products to help inform the FDA’s regulatory oversight of these products — especially as the agency considers whether it could be appropriate to exercise its authority to allow the use of CBD in dietary supplements and other foods,” Gottlieb said in a statement Tuesday.
CBD, short for cannabidiol, is a non-psychoactive compound found in the cannabis plant that promises to relax the body without altering the mind like THC. Congress legalized CBD derived from hemp in December.
This was supposed to lead to a surge in consumer products infused with the cannabis compound. However, the FDA’s rules prohibiting the addition of CBD to food and drinks have kept most large companies on the sidelines, though a number of start-ups have jumped in anyway.
Facing calls from Congress, the FDA has privately been searching for a solution. It will now take its efforts public, first with the meeting, which will take place at its headquarters near Washington, D.C. Gottlieb said the working group plans to share its findings as soon as this summer.
“This is a complicated topic and we expect that it could take some time to resolve fully,” he said. “Nevertheless, we’re deeply focused on this issue and committed to continuing to engage relevant stakeholders as we consider potential paths forward.”
The FDA and the Federal Trade Commission on Tuesday issued warning letters to three companies — Advanced Spine and Pain’s Relievus, Nutra Pure and PotNetwork Holdings — for allegedly making unproven claims about their CBD products, such as helping to treat cancer and Alzheimer’s disease.
“The FDA continues to be concerned about the proliferation of egregious medical claims being made about products asserting to contain CBD that haven’t been approved by the FDA, such as the products and companies receiving warning letters today,” Gottlieb said.
Nutra Pure President CJ Montgomery in an email to CNBC said that compared with “many other CBD-related companies making over-the-top health claims,” the language his company used was “quite minor.” He said the company removed the language “out of an abundance of caution” but is “still seeking affirmation from the FDA on the few remaining issues.”
The other two companies did not immediately respond to CNBC’s request for comment.
Source: https://www.cnbc.com/2019/04/02/fda-sets-first-hearing-on-legalizing-cannabis-compound-cbd.html
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products
For Immediate Release
April 2, 2019
Statement
In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and its components, including cannabidiol (CBD). This interest spans the range of product categories that the agency regulates. For example, we’ve seen, or heard of interest in, products containing cannabis or cannabis derivatives that are marketed as human drugs, dietary supplements, conventional foods, animal foods and drugs, and cosmetics, among other things. We also recognize that stakeholders are looking to the FDA for clarity on how our authorities apply to such products, what pathways are available to market such products lawfully under these authorities, and how the FDA is carrying out its responsibility to protect public health and safety with respect to such products.
Interest in these products increased last December when Congress passed the Agriculture Improvement Act of 2018 (the 2018 Farm Bill). Among other things, this law established a new category of cannabis classified as “hemp” – defined as cannabis and cannabis derivatives with extremely low (no more than 0.3 percent on a dry weight basis) concentrations of the psychoactive compound delta-9-tetrahydrocannabinol (THC). The 2018 Farm Bill removed hemp from the Controlled Substances Act, which means that it is no longer a controlled substance under federal law.
At the same time, Congress explicitly preserved the FDA’s current authority to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act. In doing so, Congress recognized the agency’s important public health role with respect to all the products it regulates. This allows the FDA to continue enforcing the law to protect patients and the public while also providing potential regulatory pathways, to the extent permitted by law, for products containing cannabis and cannabis-derived compounds.
When the 2018 Farm Bill became law, I issued a statement explaining the FDA’s current approach to these products and our intended next steps. Consistent with the approach and commitments described in that statement, today the FDA is announcing a number of important new steps and actions to advance our consideration of a framework for the lawful marketing of appropriate cannabis and cannabis-derived products under our existing authorities. These new steps include:
A public hearing on May 31, as well as a broader opportunity for written public comment, for stakeholders to share their experiences and challenges with these products, including information and views related to product safety.
The formation of a high-level internal agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed; including a consideration of what statutory or regulatory changes might be needed and what the impact of such marketing would be on the public health.
Updates to our webpage with answers to frequently asked questions on this topic to help members of the public understand how the FDA’s requirements apply to these products.
The issuance of multiple warning letters to companies marketing CBD products with egregious and unfounded claims that are aimed at vulnerable populations.
Public Hearing
The public hearing will give stakeholders an opportunity to provide the FDA with additional input relevant to the agency’s regulatory strategy related to existing products, as well as the lawful pathways by which appropriate products containing cannabis or cannabis-derived compounds can be marketed, and how we can make these legal pathways more predictable and efficient. We hope to gain additional information and data for the FDA to consider with respect to products containing cannabis and cannabis-derived compounds, including CBD.
As we’ve stated before, we treat products containing cannabis or cannabis-derived compounds as we do any other FDA-regulated products. Among other things, the FDA requires a cannabis product (hemp-derived or otherwise) that’s marketed with a claim of therapeutic benefit to be approved by the FDA for its intended use before it may be introduced into interstate commerce. Additionally, it is unlawful to introduce food containing added CBD, or the psychoactive compound THC, into interstate commerce, or to market CBD or THC products as dietary supplements. This is because CBD and THC are active ingredients in FDA-approved drug products and were the subject of substantial clinical investigations before they were marketed as food. In such situations, with certain exceptions that are not applicable here, the only path that the FD&C Act allows for such substances to be added to foods or marketed as dietary supplements is if the FDA first issues a regulation, through notice-and-comment rulemaking, allowing such use.
While the availability of CBD products in particular has increased dramatically in recent years, open questions remain regarding the safety considerations raised by their widespread use. For example, during its review of the marketing application for Epidiolex – a purified form of CBD that the FDA approved in 2018 for use in the treatment of certain seizure disorders – the FDA identified certain safety risks, including the potential for liver injury. These are serious risks that can be managed when the product is taken under medical supervision in accordance with the FDA-approved labeling for the product, but it is less clear how this risk might be managed in a setting where this drug substance is used far more widely, without medical supervision and not in accordance with FDA-approved labeling. There are also unresolved questions regarding the cumulative exposure to CBD if people access it across a broad range of consumer products, as well as questions regarding the intended functionality of CBD in such products. Additionally, there are open questions about whether some threshold level of CBD could be allowed in foods without undermining the drug approval process or diminishing commercial incentives for further clinical study of the relevant drug substance.
It’s critical that we address these unanswered questions about CBD and other cannabis and cannabis-derived products to help inform the FDA’s regulatory oversight of these products – especially as the agency considers whether it could be appropriate to exercise its authority to allow the use of CBD in dietary supplements and other foods. As I stated in December, the FDA would only consider this path if the agency were able to determine that all other requirements in the FD&C Act are met, including those required for food additives or new dietary ingredients.
As part of the public hearing and related public comment period, the agency is interested in whether there are particular safety concerns that we should be aware of as we consider the FDA’s regulatory oversight and monitoring of these products. For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., ingestion, absorption, inhalation) affects the safety of, and exposure to, these compounds; how cannabis and cannabis-derived compounds interact with other substances such as drug ingredients; and other questions outlined in the hearing announcement.
Additionally, we’re interested in how the incentives for, and the feasibility of, drug development with CBD and other cannabis-derived compounds would be affected if the commercial availability of products with these compounds, such as foods and dietary supplements, were to become significantly more widespread. We don’t want companies to forgo research that might support approval through the FDA’s drug review process, which could potentially lead to important safe and effective therapies. We also don’t want patients to forgo appropriate medical treatment by substituting unapproved products for approved medicines used to prevent, treat, mitigate or cure a particular disease or condition. For example, in the case of Epidiolex, the adequate and well-controlled clinical studies that supported its approval, and the assurance of manufacturing quality standards, can provide prescribers confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes. It’s important that we continue to assess whether there could be medical ramifications if patients choose to take CBD to treat certain diseases at levels higher or lower than studied in well-controlled clinical studies.
FDA Working Group
We hope that information we receive through the public hearing this May, as well as through the written public comment process, will help inform our consideration of these and other important scientific, technical and policy questions. Given the importance of these questions, and the significant public interest with respect to CBD in particular, we’re forming a high-level internal agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed. Given the importance of this issue, I’ve asked Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. and Principal Associate Commissioner for Policy Lowell Schiller, to co-chair the group and charged them with considering what options might be appropriate under our current authorities, in view of all the evidence before us and our agency’s fundamental public health mission. I’m also asking the group to consider whether there are legislative options that might lead to more efficient and appropriate pathways than might be available under current law – again, with the same science-based, public health focus that the FDA endeavors to bring to all matters before it. This is a complicated topic and we expect that it could take some time to resolve fully. Nevertheless, we're deeply focused on this issue and committed to continuing to engage relevant stakeholders as we consider potential paths forward. The working group plans to begin sharing information and/or findings with the public as early as Summer 2019.
New Compliance Actions
We’ll continue to use our authorities to take action against companies illegally selling these types of products when they are putting consumers at risk. I am deeply concerned about any circumstance where product developers make unproven claims to treat serious or life-threatening diseases, and where patients may be misled to forgo otherwise effective, available therapy and opt instead for a product that has no proven value or may cause them serious harm.
Today, the FDA is announcing that it has issued warning letters, in collaboration with the Federal Trade Commission, to three companies – Advanced Spine and Pain LLC (d/b/a Relievus), Nutra Pure LLC and PotNetwork Holdings Inc. – in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites. The companies used these online platforms to make unfounded, egregious claims about their products' ability to limit, treat or cure cancer, neurodegenerative conditions, autoimmune diseases, opioid use disorder, and other serious diseases, without sufficient evidence and the legally required FDA approval. Examples of claims made by these companies include:
“CBD successfully stopped cancer cells in multiple different cervical cancer varieties.”
“CBD also decreased human glioma cell growth and invasion, thus suggesting a possible role of CBD as an antitumor agent.”
“For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”
“Fibromyalgia is conceived as a central sensitization state with secondary hyperalgesia. CBD has demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms responsible for the pain associated with migraines, fibromyalgia, IBS and other related disorders.”
“Cannabidiol May be Effective for Treating Substance Use Disorders.”
“CBD reduced the rewarding effects of morphine and reduced drug seeking of heroin.”
“CBD may be used to avoid or reduce withdrawal symptoms.”
I believe these are egregious, over-the-line claims and we won’t tolerate this kind of deceptive marketing to vulnerable patients. The FDA continues to be concerned about the proliferation of egregious medical claims being made about products asserting to contain CBD that haven’t been approved by the FDA, such as the products and companies receiving warning letters today. CBD is marketed in a variety of product types, such as oil drops, capsules, syrups, teas and topical lotions and creams. Often such products are sold online and are therefore available throughout the country.
Selling unapproved products with unsubstantiated therapeutic claims can put patients and consumers at risk. These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases. Additionally, because they are not evaluated by the FDA, there may be other ingredients that are not disclosed, which may be harmful.
As our actions today make clear, the FDA stands ready to protect consumers from companies illegally selling CBD products that claim to prevent, diagnose, treat, or cure serious diseases, such as cancer, Alzheimer’s disease, psychiatric disorders and diabetes. The agency has and will continue to monitor the marketplace and take enforcement action as needed to protect the public health against companies illegally selling cannabis and cannabis-derived products that can put consumers at risk and are being marketed and distributed in violation of the FDA’s authorities.
Ultimately, we remain committed to exploring an appropriate, efficient and predictable regulatory framework to allow product developers that meet the requirements under our authorities to lawfully market these types of products. The actions we’re announcing today will allow us to continue to clarify our regulatory authority over these products and seek input from a broad range of stakeholders and examine a variety of approaches and considerations in the marketing and regulation of cannabis or cannabis-derived products, while continuing to protect the public’s health and safety.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635048.htm
Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds
An unpublished Proposed Rule by the Food and Drug Administration on 04/03/2019
https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-06436.pdf
https://www.federalregister.gov/documents/2019/04/03/2019-06436/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds
Oh, so now a "known scam" going on big multi-day runs or maybe longer?
Looks like a 24 month uptrend? Or more?
Probably time to play earnings season and buy the dips heading into quarterly reports?
Quarterly growth might be greater than 50%, now with hemp free to be a traded ag commodity?
Hemp Inc helping industry get off the ground coast-to-coast, and internationally, you saying you don't see one postive thing in this company, or its long term potential?
Awards, international exposure, news articles, 50% quarterly rev growth and all before hemp nationally legalized, most people just beginning to enter this market have Hemp Inc and few others to thank.
Yet so many invalid, unverfied information circulating, like that someone believes an actual trail has been motioned and granted, but no actual facts/data/info.
Why?
The way HEMP INC rolls
Like 50% quarterly rev growth prior to national hemp legalization?
Oh, we roll'n. Pre-roll'n. After-roll'n. Truckload after sweet, beautiful truckload "ROLL'N".
WELCOME TO THE #1 HEMP COMPANY ON THE PLANET.
MAKE AMERICA HEMP AGAIN.
Hemp Inc rolling through FLOODGATES.
"News" lol...
sad.
RSI, STO, and MACD turning over, pointing north...
BIG golden cross setting up on the weekly...
And Bruce adds a few dozen more FB followers in the past few days.
Now at over 8100 followers.
but MAYBE they are FAKE facebook accounts? Paid to follow?
LOL, surprised I thought of it first!
Farm Act positions NC as leader in hemp production
March 31, 2019 Yadkin Ripple
Staff Report
RALEIGH — Sen. Brent Jackson (R-Sampson) announced the NC Farm Act of 2019, which uses recent federal rule changes to establish a regulatory framework for expanded hemp production in North Carolina. Jackson was joined by Senators Norm Sanderson (R-Pamlico), Todd Johnson (R-Union), Harry Brown (R-Onslow), Vickie Sawyer (R-Iredell), Chuck Edwards (R-Henderson), Tom McInnis (R-Richmond), and Agriculture Commissioner Steve Troxler.
Jackson said, “Now is the time to act to position North Carolina as a national leader in hemp production. The U.S. Department of Agriculture is finalizing new regulations, and the Farm Act will allow our state to move forward immediately upon federal approval. This is a potential boom industry, and we need to be ready to compete.”
Troxler said, “By passing the Farm Act, North Carolina will have the guidelines in place for a hemp program that is compliant with federal law, protects public health, and fosters growth in the state’s agriculture industry.”
Sanderson said, “A large percent of what has for decades been North Carolina’s primary farm money crop has been lost through the reduction in tobacco growth. Because of its many uses, the hemp production industry has the potential to provide North Carolina farmers with an additional source of desperately needed income. It is the responsibility of the State to take the lead in the oversight of this newly growing industry. This Farm Bill starts that process.”
Johnson said, “Thank you to Senator Jackson and Commissioner Troxler for their work to continue to strengthen North Carolina’s agriculture industry. This bill’s focus on setting our state up to be a leader in the emerging hemp market displays the type of foresight that has made us so successful.”
Larry Wooten, president of the N.C. Farm Bureau, said, “North Carolina Farm Bureau appreciates the legislature’s continued work to lessen the regulatory burden that all too often weighs down North Carolina’s farmers and agribusinesses. Agriculture is North Carolina’s largest industry, but it is struggling because of, among other factors, bad weather, tough trade negotiations and low commodity prices. As with the previous six Farm Acts that have been enacted since 2013, this legislation is an important tool that will help North Carolina’s farmers remain competitive and continue to grow North Carolina’s number one economic driver.”
The federal government recently acted to bring laws governing hemp production in the United States in line with much of the world. Previously, Congress permitted only small-scale hemp pilot programs, which North Carolina adopted successfully. The 2018 Federal Farm Bill allows for wide-scale hemp production provided states adopt stringent licensing and enforcement standards.
Federal law requires hemp to contain less than 0.3 percent THC, which is a very small fraction of the THC contained in marijuana plants. The rules imposed by the 2018 federal farm bill require states to implement regulations to license hemp producers and to closely monitor the THC levels in their product.
To comply with those requirements, The NC Farm Act of 2019 establishes the North Carolina Hemp Commission, sets forth qualifications for hemp production licensees (including prohibitions on licenses to individuals with past drug offenses), and defines civil and criminal penalties for producers who violate the law. The bill also requires a valid license to market and sell cannabinoid-related products, including CBD oil.
Source: https://www.yadkinripple.com/news/13426/farm-act-positions-nc-as-leader-in-hemp-production
THE WHO'S-WHO OF HEMP MANIPULATION
Who could it be?
McCloy?
Kuznetsov?
Yudell?
Who the 'F' is "Larry"?
Who are the key players?
Bruce getting blindsided by sleazy brokers and traders. Bad players. Most likely why the TA was ordered not to disclose confidential information, protecting the stock from MANIPULATORS. Or maybe Barry slipped up? Maybe he sold too much too fast. Maybe he takes the fine, and leaves Bruce on his own?
And if it weren't for the 3 year old dying complaint, HEMP would STILL be filing on OTC Markets.
The damages against this company due to a hastily pressed case on loose hearsay could be enough to bring forth a massive counter suit. Wouldn't want to be on the other side of the table once the table turns.
And Shareholders will thank them for the FREE SEC audit. Perhaps at that time it might be time to decide whether to uplist?
Allegations made, but here we are... zero evidence.
Doors still open for business. April sowing right around the corner.
FLOODGATES
Yes, and anyone caught trying to manipulate HEMP are going to met with a junior sized bed in a jail cell.
Looks like maybe some outsiders are trying to manipulate?
I see some think that CBD is different in hemp and MJ, or that there is an actual court date set for trial. That kind of manipulation, you think, is affecting stock or shareholders?
Penny stocks also a place where some companies go from OTC to Nasdaq, with 3000% gains, most often in sector waves, driven by hot markets or deregulation.
You think HEMP is hot market with deregulation?
They have the option to extend and can use as seen fit.
Per SEC guidelines, all companies have the right to extend by filing a form 12b-25.
https://www.sec.gov/Archives/edgar/data/1500341/000119312513126179/d469007dnt10q.htm
HEMP has filed for an extension virtually each and every time prior to issuing the Q's and K's.
There really isn't any indicating that the extension is any sign of weakness or strength. It's just simply there, and if a CEO wishes to exercise the extension (perhaps to disclose a few more deals, or include more news or events).
Lots of people getting excited tho, and anxious to see the progress made at Hemp Inc.
So far, 50% quarterly rev growth, but only with a product line secondary to the vast of tens of thousands of uses for hemp...
With hemp finally coming off the national ball-and-chain, and several MEGA retailers already buying in, do you think earnings likely slowing or accelerating?
Impatient shareholder publicly expresses lack of intelligence;
CEO, Bruce Perlowin humorously provides direct response.
Guys name is Steve Briers, it's all over the internet, not sure the need to blackout part of his name, lol.
The extension is always filed and fins always arrive on time. It's another NON ISSUE.
We all know the fins are soon to arrive, the '18 annual, then followed by Q1 '19. EARNINGS SEASON
Industry dying?
or
FLOODGATES
ROSEBUD ORIGINAL VIDEO: A Day at Hemp University
by Gracie SolisMonday, March 25th 2019
Hemp Inc. hosted their first educational seminar, "Hemp University" Saturday at Southern Oregon University in Ashland. The full day was packed with guest speakers who covered every aspect of industrial hemp, from farming, to sustainability, business plans and investments. The key note speaker was Hemp Inc. CEO, Bruce Perlowin. The event is aimed at helping farmers and entrepreneurs transition to industrial hemp with the know-how, connections and a sense of community.
The room was overflowing with about 200 people in attendance. Perlowin plans to make these seminars more common here in the valley, hoping to put on a new Hemp University every six weeks.
Source: https://mailtribune.com/so-famous-cannabis/hemp-university-southern-oregon?fbclid=IwAR18aW1EqM_quANMuDxYa5ZX3ZOTU-jcrrhPHMiqa-t7m0tEmZV1OVTeqk8
FLOODGATES
What happens when farmers need to "DUMP" their hemp on a processor that can handle all the excess hemp being grown by the tens of hundreds of thousands of acres?
You think they'll need a big machine to do that?
What that is?
Could it be?
For shorts? Agreed.
You Can Now Buy CBD on Walmart.com
The CBD industry is moving quickly now...
Susie Peterson by Susie Peterson March 27, 2019 in Business, Investments, United States
Back in October 2018, the Canadian division of Walmart said that it was exploring the idea of selling cannabis-based products on their shelves, sending shares of Walmart Inc. (NYSE:WMT) up roughly 3% despite no concrete plans to do so anytime soon.
A few months later in the U.S., the Agriculture Improvement Act of 2018, a.k.a. the Farm Bill was passed. This made a legal distinction between cannabis and hemp and defined hemp as “any part of the Cannabis sativa L plant, including all derivatives and extracts such as cannabidiol (CBD), provided that the plant contains less than 0.3% tetrahydrocannabinol (THC).”
Fast forward to today, and you can buy CBD supplements on Walmart.com, buy CBD beauty products on Ulta.com, and it’s rapidly spreading across the country in retailers ranging from Neiman Marcus and Sephora to CVS and Walgreens.
CBD at Walmart
Currently, Walmart.com only offers a limited selection of CBD products from only two brands – Procanna and Medterra. That said, there’s a little of everything.
You can get CBD tinctures for humans or for animals. You can also get CBD softgels for humans or for animals. Also, surprisingly, you can get a disposable CBD vape pen.
It is worth noting that all of the CBD products available through Walmart are sold and shipped by discount vitamin seller VitaSprings, which also sells a wide variety of other vitamins and nutritional supplements through the Walmart Marketplace.
Conclusion
Chances are, it will be a little while before Walmart itself begins selling CBD. That said, there seems to be another major retailer going green every day. After all, shares of Walgreens Boots Alliance Inc. (NASDAQ:WBA) are already up and it has been one hour since the news broke.
In the meantime, be sure to subscribe to updates here so you never miss an important development.
Source: https://mjobserver.com/business/you-can-now-buy-cbd-cannabidiol-on-walmart-com/